ensituximab
mAbexperimental
Ensituximab (NPC-1C) is a chimeric monoclonal antibody under development for as a candidate for treatment of cancers. The target of the antibody is uncertain and is described as "human colorectal and pancreatic carcinoma-associated antigens", a set of tumor antigens isolated from human cancers. The target might be Mucin 5AC. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2012 (NCT01040000)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEnsituximab ↗
- ChEMBLCHEMBL1743013 ↗
Also known as
- ensituximab
- ensituximab
- npc-1c
- npc-1c
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01834235 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2013 | Precision Biologics, Inc |
| NCT01040000 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2012 | Precision Biologics, Inc |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Precision Biologics, Inc | For profit | 2 | 2 | 1 | 2012 |
1 organizations
Page 1 / 1